Evicenter
P&T meetings

SKY-0515

Huntington's disease

211 sources

Section 6 of 6

References

211 sources

  1. Achenbach and Saft (2021) (opens in a new tab)
  2. Ajitkumar et al. (2025) (opens in a new tab)
  3. AMCP (2024) (opens in a new tab)
  4. American Academy of Neurology (2022) (opens in a new tab)
  5. American Academy of Neurology movement disorders quality measures (opens in a new tab)
  6. Anderson et al. (2018) (opens in a new tab)
  7. Andriessen et al. (2025) (opens in a new tab)
  8. ANZCTR ACTRN12623001161617 (opens in a new tab)
  9. ANZCTR ACTRN12624000602527 (opens in a new tab)
  10. Armstrong and Miyasaki (2012) (opens in a new tab)
  11. Bachoud-Lévi et al. (2019) (opens in a new tab)
  12. Baig et al. (2016) (opens in a new tab)
  13. Bardakjian et al. (2019) (opens in a new tab)
  14. Barer et al. (2023) (opens in a new tab)
  15. Bates et al. (2015) (opens in a new tab)
  16. Bayen et al. (2023) (opens in a new tab)
  17. Bean et al. (2014) (opens in a new tab)
  18. Boersema-Wijma et al. (2023) (opens in a new tab)
  19. Bombard et al. (2009) (opens in a new tab)
  20. Bruzelius et al. (2019) (opens in a new tab)
  21. Burgunder et al. (2011) (opens in a new tab)
  22. Byrne et al. (2017) (opens in a new tab)
  23. Caldeira Brás et al. (2026) (opens in a new tab)
  24. Carlozzi et al. (2016) (opens in a new tab)
  25. Carlozzi et al. (2017) (opens in a new tab)
  26. Chen et al. (2024) (opens in a new tab)
  27. Christensen et al. (2022) (opens in a new tab)
  28. Claassen et al. (2017) (opens in a new tab)
  29. Claassen et al. (2021) (opens in a new tab)
  30. Claassen et al. (2022) (opens in a new tab)
  31. ClinicalTrials.gov NCT03628235 (opens in a new tab)
  32. ClinicalTrials.gov NCT06873334 (opens in a new tab)
  33. ClinicalTrials.gov NCT07378644 (opens in a new tab)
  34. ClinicalTrials.gov NCT07537075 (opens in a new tab)
  35. Coppen and Roos (2017) (opens in a new tab)
  36. da Silva van der Laan et al. (2024) (opens in a new tab)
  37. DailyMed AUSTEDO prescribing information (2025) (opens in a new tab)
  38. DailyMed INGREZZA prescribing information (2026) (opens in a new tab)
  39. DailyMed XENAZINE prescribing information (2019) (opens in a new tab)
  40. Divino et al. (2013) (opens in a new tab)
  41. Dorey et al. (2016) (opens in a new tab)
  42. Drug Discovery and Development (2023) (opens in a new tab)
  43. Ekkel et al. (2023) (opens in a new tab)
  44. El-Sourady et al. (2022) (opens in a new tab)
  45. Erwin et al. (2010) (opens in a new tab)
  46. Evans et al. (2013) (opens in a new tab)
  47. Exuzides et al. (2021) (opens in a new tab)
  48. Exuzides et al. (2022a) (opens in a new tab)
  49. Exuzides et al. (2022b) (opens in a new tab)
  50. Exuzides et al. (2022c) (opens in a new tab)
  51. Farag et al. (2026) (opens in a new tab)
  52. Ferreira et al. (2022) (opens in a new tab)
  53. Fisher and Hayden (2014) (opens in a new tab)
  54. Fox and Harding (2026) (opens in a new tab)
  55. Frank et al. (2025) (opens in a new tab)
  56. Frisch et al. (2026) (opens in a new tab)
  57. Furby et al. (2022) (opens in a new tab)
  58. Furr Stimming et al. (2023) (opens in a new tab)
  59. Furr Stimming et al. (2025) (opens in a new tab)
  60. Furr Stimming et al. (2026) (opens in a new tab)
  61. Fusilli et al. (2018) (opens in a new tab)
  62. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015) (opens in a new tab)
  63. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019) (opens in a new tab)
  64. Gokhale and Villa Zapata (2025) (opens in a new tab)
  65. Grimbergen et al. (2008) (opens in a new tab)
  66. Guzauskas et al. (2024) (opens in a new tab)
  67. Hall et al. (2025) (opens in a new tab)
  68. Handsaker et al. (2025) (opens in a new tab)
  69. Harding (2025) (opens in a new tab)
  70. Harding (2026a) (opens in a new tab)
  71. Harding (2026b) (opens in a new tab)
  72. Harrison et al. (2023) (opens in a new tab)
  73. Hawkins et al. (2013) (opens in a new tab)
  74. Hawton et al. (2019) (opens in a new tab)
  75. Heemskerk and Roos (2012) (opens in a new tab)
  76. Hensman Moss et al. (2017) (opens in a new tab)
  77. Hergert et al. (2021) (opens in a new tab)
  78. Hernandez (2024) (opens in a new tab)
  79. Hernandez (2026a) (opens in a new tab)
  80. Hernandez (2026b) (opens in a new tab)
  81. Herzog-Krzywoszanska and Krzywoszanski (2019) (opens in a new tab)
  82. Ho et al. (2009) (opens in a new tab)
  83. Hubers et al. (2012) (opens in a new tab)
  84. Hubers et al. (2013) (opens in a new tab)
  85. Huntington Study Group (2006) (opens in a new tab)
  86. Huntington Study Group (2016) (opens in a new tab)
  87. Huntington's Disease News (2026) (opens in a new tab)
  88. Huntington's Disease Society of America (2011) (opens in a new tab)
  89. Huntington's Disease Society of America (2020) (opens in a new tab)
  90. Huntington's Disease Society of America Centers of Excellence (opens in a new tab)
  91. Huntington's Disease Society of America genetic testing and your rights (opens in a new tab)
  92. ICER (2026) (opens in a new tab)
  93. ICER draft scope (2026) (opens in a new tab)
  94. ICER reference case (2025) (opens in a new tab)
  95. Inbar et al. (2026) (opens in a new tab)
  96. Johnson et al. (2018) (opens in a new tab)
  97. Jones et al. (2016) (opens in a new tab)
  98. Kachian et al. (2019) (opens in a new tab)
  99. Kay et al. (2016) (opens in a new tab)
  100. Keum et al. (2016) (opens in a new tab)
  101. Kim et al. (2024) (opens in a new tab)
  102. Knott et al. (2024) (opens in a new tab)
  103. Ko et al. (2020) (opens in a new tab)
  104. Langbehn et al. (2004) (opens in a new tab)
  105. Langbehn et al. (2019) (opens in a new tab)
  106. Lee et al. (2022) (opens in a new tab)
  107. Lee et al. (2024) (opens in a new tab)
  108. MacLeod et al. (2013) (opens in a new tab)
  109. Managed Healthcare Executive (2023) (opens in a new tab)
  110. Martinez-Horta et al. (2016) (opens in a new tab)
  111. Massey et al. (2021) (opens in a new tab)
  112. McColgan and Tabrizi (2018) (opens in a new tab)
  113. McColgan et al. (2023) (opens in a new tab)
  114. McLean et al. (2024) (opens in a new tab)
  115. Medina et al. (2022) (opens in a new tab)
  116. MedlinePlus (2020) (opens in a new tab)
  117. Mestre et al. (2009a) (opens in a new tab)
  118. Mestre et al. (2009b) (opens in a new tab)
  119. Miller et al. (2026a) (opens in a new tab)
  120. Miller et al. (2026b) (opens in a new tab)
  121. Mills et al. (2024) (opens in a new tab)
  122. Morrison et al. (2011) (opens in a new tab)
  123. Mühlbäck et al. (2023) (opens in a new tab)
  124. NINDS (2026) (opens in a new tab)
  125. Ogilvie et al. (2025) (opens in a new tab)
  126. Ogilvie et al. (2026) (opens in a new tab)
  127. Ohlmeier et al. (2019) (opens in a new tab)
  128. Oosterloo et al. (2024) (opens in a new tab)
  129. Oster et al. (2008) (opens in a new tab)
  130. Patel et al. (2023) (opens in a new tab)
  131. Patil et al. (2025) (opens in a new tab)
  132. Patil et al. (2026) (opens in a new tab)
  133. Paulsen et al. (2001) (opens in a new tab)
  134. Paulsen et al. (2014) (opens in a new tab)
  135. Pollard et al. (2024) (opens in a new tab)
  136. Poprelka et al. (2025) (opens in a new tab)
  137. Pringsheim et al. (2012) (opens in a new tab)
  138. PTC Therapeutics (2026) (opens in a new tab)
  139. Quinn et al. (2020) (opens in a new tab)
  140. Rawlins et al. (2016) (opens in a new tab)
  141. Reilmann (2013) (opens in a new tab)
  142. Reilmann et al. (2014) (opens in a new tab)
  143. Reilmann et al. (2025) (opens in a new tab)
  144. Research and Markets (2026) (opens in a new tab)
  145. Roche (2021) (opens in a new tab)
  146. Rodrigues and Ferreira (2017b) (opens in a new tab)
  147. Rodrigues et al. (2017a) (opens in a new tab)
  148. Rodriguez Santana et al. (2022) (opens in a new tab)
  149. Rodríguez Santana et al. (2025) (opens in a new tab)
  150. Rodríguez-Santana et al. (2021) (opens in a new tab)
  151. Rodríguez-Santana et al. (2023) (opens in a new tab)
  152. Roiboit and Stout (2026) (opens in a new tab)
  153. Roos (2010) (opens in a new tab)
  154. Saft et al. (2023) (opens in a new tab)
  155. Sampaio et al. (2024) (opens in a new tab)
  156. Sawant et al. (2024) (opens in a new tab)
  157. Schobel et al. (2017) (opens in a new tab)
  158. Sellers et al. (2020) (opens in a new tab)
  159. Shaw et al. (2022a) (opens in a new tab)
  160. Shaw et al. (2022b) (opens in a new tab)
  161. Silva-Paredes et al. (2019) (opens in a new tab)
  162. Skyhawk Therapeutics chief commercial officer announcement (2026) (opens in a new tab)
  163. Skyhawk Therapeutics community letter (2026) (opens in a new tab)
  164. Skyhawk Therapeutics EHDN 2024 presentation announcement (2024) (opens in a new tab)
  165. Skyhawk Therapeutics FALCON-HD expansion announcement (2026) (opens in a new tab)
  166. Skyhawk Therapeutics FALCON-HD first patient dosed announcement (2025) (opens in a new tab)
  167. Skyhawk Therapeutics fifteen-month results announcement (2026) (opens in a new tab)
  168. Skyhawk Therapeutics first interim results announcement (2025) (opens in a new tab)
  169. Skyhawk Therapeutics nine-month results announcement (2026) (opens in a new tab)
  170. Skyhawk Therapeutics phase 1 topline results announcement (2024) (opens in a new tab)
  171. Skyhawk Therapeutics TGA eligibility announcement (2026) (opens in a new tab)
  172. Skyhawk Therapeutics treatment duration extension announcement (2024) (opens in a new tab)
  173. Skyhawk Therapeutics twelve-month cUHDRS subcomponent announcement (2026) (opens in a new tab)
  174. Skyhawk Therapeutics twelve-month results announcement (2026) (opens in a new tab)
  175. Smith et al. (2026) (opens in a new tab)
  176. Snowden (2017) (opens in a new tab)
  177. Sokol et al. (2022) (opens in a new tab)
  178. Sokol et al. (2023) (opens in a new tab)
  179. Solberg et al. (2018) (opens in a new tab)
  180. Stoker et al. (2022) (opens in a new tab)
  181. Sullivan et al. (2014) (opens in a new tab)
  182. Tabrizi et al. (2013) (opens in a new tab)
  183. Tabrizi et al. (2020) (opens in a new tab)
  184. Tabrizi et al. (2022) (opens in a new tab)
  185. Tarolli et al. (2017) (opens in a new tab)
  186. Thorley et al. (2018) (opens in a new tab)
  187. To et al. (2022) (opens in a new tab)
  188. To et al. (2023) (opens in a new tab)
  189. Trundell et al. (2018) (opens in a new tab)
  190. Trundell et al. (2019) (opens in a new tab)
  191. uniQure (2025) (opens in a new tab)
  192. uniQure BLA plan announcement (2026) (opens in a new tab)
  193. uniQure BLA submission announcement (2026) (opens in a new tab)
  194. uniQure regulatory update (2026) (opens in a new tab)
  195. van der Zwaan et al. (2022) (opens in a new tab)
  196. van Walsem et al. (2022) (opens in a new tab)
  197. Vonsattel et al. (1985) (opens in a new tab)
  198. Walker (2007) (opens in a new tab)
  199. Watkins et al. (2018) (opens in a new tab)
  200. Wesson et al. (2018) (opens in a new tab)
  201. Wexler et al. (2016) (opens in a new tab)
  202. Wheelock et al. (2003) (opens in a new tab)
  203. Willock et al. (2021) (opens in a new tab)
  204. Willock et al. (2023) (opens in a new tab)
  205. Winder et al. (2018) (opens in a new tab)
  206. Yohrling et al. (2019) (opens in a new tab)
  207. Yohrling et al. (2020) (opens in a new tab)
  208. Young et al. (2026) (opens in a new tab)
  209. Youssov et al. (2022) (opens in a new tab)
  210. Youssov et al. (2025) (opens in a new tab)
  211. Yu et al. (2019) (opens in a new tab)